Recent studies have identified some of the genetic alterations involved in
endometrial carcinoma development. Transforming genes, including K-ras and
c-erbB2/neu oncogenes and the p53, PTEN and hMLH1 tumor suppressor genes, a
re the most frequently altered. In addition, endometrial carcinomas express
high levels of chemoresistance markers, including the MDR-1 or the MRP gen
es. The genetic background of an endometrial cancer patient may include hig
h-penetrance genes such as the DNA mismatch repair genes causing microsatel
lite instability, and low-penetrance genes such as those involved in estrog
en-metabolism. The spectrum of several molecular lesions suggest a model fo
r endometrial tumorigenesis through two divergent pathways, and which may i
mprove the design of more rational therapeutic agents.